<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701074</url>
  </required_header>
  <id_info>
    <org_study_id>15-081/730216-8</org_study_id>
    <nct_id>NCT03701074</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus</brief_title>
  <official_title>Single Center, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to determine whether treatment of hemodynamically&#xD;
      significant patent ductus arteriosus with a combined therapy of intravenous Ibuprofen and&#xD;
      oral acetaminophen has higher success rate in closing the ductus arteriosus than a standard&#xD;
      treatment strategy of using intravenous ibuprofen alone among preterm infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of the study are to confirm the safety of oral acetaminophen in&#xD;
      extremely low birth infants, given concomitantly with intravenous ibuprofen and also to&#xD;
      determine its efficacy in significantly increasing the rates of ductal closure when compared&#xD;
      to only intravenous ibuprofen therapy. Hence primary outcome variable include patent ductus&#xD;
      arteriosus closure success rate, based on the 2-D transthoracic echocardiographic evidence.&#xD;
&#xD;
      This study is a single center, randomized, double blinded, placebo controlled trial. Preterm&#xD;
      infants with gestational age of with a gestational age ≤27 6/7 weeks by the best obstetric&#xD;
      estimate are eligible for enrollment.&#xD;
&#xD;
      For randomization, the study population will be stratified to two subgroups based on&#xD;
      gestational age (GA ≤24 weeks and &gt; 25 weeks). Randomization will occur by using computer&#xD;
      generated random sequence, using a 4-block design, with 1:1 parallel allocation. Allocations&#xD;
      include treatment and control arm. Treatment arm will receive combination of intravenous&#xD;
      ibuprofen and oral acetaminophen, while control arm will receive intravenous Ibuprofen and&#xD;
      oral placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    very slow enrollment. Only one patient enrolled. Termination by PI&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2018</start_date>
  <completion_date type="Actual">December 2, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ductus Arteriosus Closure/Constriction Rate</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Ductal closure/constriction rate as defined based on the echocardiographic findings. Ductal closure/constriction will be defined as the complete closure of ductus or ductal diameter &lt;1 mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Patent Ductus Arteriosus Parameters Before and After the Study Intervention</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory Settings Before and After the Study Intervention</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Liver Injury</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>liver enzymes before and after the study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Renal Injury</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Blood urea nitrogen (BUN) and serum creatinine before and after the study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hematological Adverse Events</measure>
    <time_frame>24-48 hours after the completion of study intervention</time_frame>
    <description>Hematocrit and platelets before and after the study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Days of Mechanical Ventilation</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Days of Need for Supplemental Oxygen</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Noninvasive Ventilation</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Persistence of Ductus-needing Pharmacological Treatment</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Ligation of PDA</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Bronchopulmonary Dysplasia</measure>
    <time_frame>at 36 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants Requiring Home Oxygen Therapy</measure>
    <time_frame>at discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Before Discharge</measure>
    <time_frame>until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Full Enteral Feeding</measure>
    <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
    <description>Time to achieve 120 ml/kg/day of enteral feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Total Parenteral Nutrition</measure>
    <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of Prematurity</measure>
    <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Spontaneous Intestinal Perforation</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Necrotizing Enterocolitis</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Gastrointestinal Hemorrhage</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Late Onset Sepsis</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Periventricular Leukomalacia</measure>
    <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <condition>Preterm Infant</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>ibuprofen and acetaminophen arm (intervention arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen and placebo arm (control arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen and acetaminophen</intervention_name>
    <description>Intravenous ibuprofen given concomitantly with oral acetaminophen</description>
    <arm_group_label>ibuprofen and acetaminophen arm (intervention arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen and placebo</intervention_name>
    <description>Intravenous ibuprofen given concomitantly with oral placebo</description>
    <arm_group_label>ibuprofen and placebo arm (control arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Preterm infant ≤27 6/7&#xD;
&#xD;
          2. Written parental consent is obtained&#xD;
&#xD;
          3. Infant requires respiratory support&#xD;
&#xD;
          4. diagnosis of a persistent patent ductus arteriosus after 5 days of age, (defined as at&#xD;
             least two of the following:&#xD;
&#xD;
               1. Ductus size ≥ 1.5 mm&#xD;
&#xD;
               2. Maximum flow velocity through the ductus ≤ 2 m/s&#xD;
&#xD;
               3. Left atrium to aorta ratio ≥ 1.4&#xD;
&#xD;
               4. Wide pulse pressure&#xD;
&#xD;
               5. B-type natriuretic peptide (BNP)&#xD;
&#xD;
          5. Attending neonatologist made decision to treat patent ductus arteriosus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No parental consent&#xD;
&#xD;
          2. Infants &gt; 21days of postnatal age&#xD;
&#xD;
          3. Congenital anomalies such as cardiac or multiple anomalies&#xD;
&#xD;
          4. Infection (e.g., septicemia, pneumonia)&#xD;
&#xD;
          5. Bleeding disorder or platelet count&lt; 50,000/ml&#xD;
&#xD;
          6. Acute kidney injury (AKI)defined as oliguria (urine output&lt; 0.5 ml/kg/hr for 16hrs)&#xD;
             and/or serum creatinine &gt; 1.5 mg/dl&#xD;
&#xD;
          7. Elevated liver enzymes (&gt;2 fold from upper normal limits)&#xD;
&#xD;
          8. Pulmonary hypertension or right to left shunt through the ductus arteriosus&#xD;
&#xD;
          9. Diagnosis of necrotizing enterocolitis&#xD;
&#xD;
         10. Unable to tolerate oral medications at the time of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Eyal, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of South Alabama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <results_first_submitted>April 18, 2021</results_first_submitted>
  <results_first_submitted_qc>April 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Alabama</investigator_affiliation>
    <investigator_full_name>Ramachandra Bhat</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>patent ductus arteriosus</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>bronchopulmonary dysplasia</keyword>
  <keyword>mechanical ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT03701074/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall screening for the study enrollment started 12/15/2018. Screening was continued until 10/30/2020. The study was conducted at the Neonatal Intensive Care Unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibuprofen and Acetaminophen Arm (Intervention Arm)</title>
          <description>ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).&#xD;
Ibuprofen and acetaminophen: Intravenous ibuprofen given concomitantly with oral acetaminophen</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen and Placebo Arm (Control Arm)</title>
          <description>ibuprofen and placebo will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.&#xD;
Ibuprofen and placebo: Intravenous ibuprofen given concomitantly with oral placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Treatment was withdrawn after the 10th dose of oral medication (acetaminophen), on day 3 of treatment, as the infant developed mild abdominal distension which was as per the study protocol</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall only one infant was enrolled into the study. Hence, control arm had no patient enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Ibuprofen and Acetaminophen Arm (Intervention Arm)</title>
          <description>ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).&#xD;
Ibuprofen and acetaminophen: Intravenous ibuprofen given concomitantly with oral acetaminophen</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen and Placebo Arm (Control Arm)</title>
          <description>ibuprofen and placebo will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.&#xD;
Ibuprofen and placebo: Intravenous ibuprofen given concomitantly with oral placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PDA size</title>
          <units>mm</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5"/>
                    <measurement group_id="B3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ductus Arteriosus Closure/Constriction Rate</title>
        <description>Ductal closure/constriction rate as defined based on the echocardiographic findings. Ductal closure/constriction will be defined as the complete closure of ductus or ductal diameter &lt;1 mm</description>
        <time_frame>24-48 hours after the completion of study intervention</time_frame>
        <population>None were enrolled for the control arm</population>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen and Acetaminophen Arm (Intervention Arm)</title>
            <description>ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).&#xD;
Ibuprofen and acetaminophen: Intravenous ibuprofen given concomitantly with oral acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen and Placebo Arm (Control Arm)</title>
            <description>ibuprofen and placebo will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.&#xD;
Ibuprofen and placebo: Intravenous ibuprofen given concomitantly with oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ductus Arteriosus Closure/Constriction Rate</title>
          <description>Ductal closure/constriction rate as defined based on the echocardiographic findings. Ductal closure/constriction will be defined as the complete closure of ductus or ductal diameter &lt;1 mm</description>
          <population>None were enrolled for the control arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Patent Ductus Arteriosus Parameters Before and After the Study Intervention</title>
        <time_frame>24-48 hours after the completion of study intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilatory Settings Before and After the Study Intervention</title>
        <time_frame>24-48 hours after the completion of study intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Liver Injury</title>
        <description>liver enzymes before and after the study intervention</description>
        <time_frame>24-48 hours after the completion of study intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Renal Injury</title>
        <description>Blood urea nitrogen (BUN) and serum creatinine before and after the study intervention</description>
        <time_frame>24-48 hours after the completion of study intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hematological Adverse Events</title>
        <description>Hematocrit and platelets before and after the study intervention</description>
        <time_frame>24-48 hours after the completion of study intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Days of Mechanical Ventilation</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Days of Need for Supplemental Oxygen</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Noninvasive Ventilation</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Persistence of Ductus-needing Pharmacological Treatment</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Surgical Ligation of PDA</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Bronchopulmonary Dysplasia</title>
        <time_frame>at 36 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Infants Requiring Home Oxygen Therapy</title>
        <time_frame>at discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Before Discharge</title>
        <time_frame>until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Full Enteral Feeding</title>
        <description>Time to achieve 120 ml/kg/day of enteral feeding</description>
        <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Total Parenteral Nutrition</title>
        <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinopathy of Prematurity</title>
        <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Spontaneous Intestinal Perforation</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Necrotizing Enterocolitis</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Gastrointestinal Hemorrhage</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Late Onset Sepsis</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>from birth until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Periventricular Leukomalacia</title>
        <time_frame>from randomization until discharge/40 weeks post menstrual age</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>None were enrolled into control arm, Therefore, number infants at risk for adverse events under the control arm are zero</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibuprofen and Acetaminophen Arm (Intervention Arm)</title>
          <description>ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).&#xD;
Ibuprofen and acetaminophen: Intravenous ibuprofen given concomitantly with oral acetaminophen</description>
        </group>
        <group group_id="E2">
          <title>Ibuprofen and Placebo Arm (Control Arm)</title>
          <description>ibuprofen and placebo will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants &gt; 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.&#xD;
Ibuprofen and placebo: Intravenous ibuprofen given concomitantly with oral placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Biochemical evidence of acute kidney injury with preserved renal function, probably nor related to i</sub_title>
                <description>As per the study protocol, after the completion of study intervention, kidney function was monitored using BUN and serum creatinine. S. creatinine was noted to be 2 times above the baseline pre-intervention level (1.28 mg/dl). Renal function normal</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ramachandra Bhat</name_or_title>
      <organization>University of South Alabama</organization>
      <phone>2514151055</phone>
      <email>rbhat@health.southalabama.edu; rambhat79@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

